BOULDER, Colo., May 9, 2018 /PRNewswire/ -- Array BioPharma
Inc., (Nasdaq: ARRY) today reported results for its third quarter
of fiscal 2018 and provided an update on the progress of its key
clinical development programs.
"Preparations for the anticipated U.S. launch of encorafenib and
binimetinib in BRAF-mutant melanoma are well underway," said
Ron Squarer, Chief Executive Officer. "We are pleased to have our
entire commercial leadership and infrastructure in place and are
poised for an exciting 2018, as we look ahead to commercialization
and additional data updates from our encorafenib and binimetinib
clinical trials."
COLUMBUS PHASE 3 TRIAL
Regulatory
Array's
New Drug Applications (NDAs) to support use of the encorafenib and
binimetinib combination for the treatment of patients with
BRAF-mutant advanced, unresectable or metastatic melanoma
remain under review by the FDA with a target action date under
Prescription Drug User Fee Act (PDUFA) of June 30, 2018.
The European Medicines Agency (EMA), as well as the Swiss
Medicines Agency (Swissmedic) and the Australian Therapeutic Goods
Administration (TGA), are reviewing the Marketing Authorization
Applications (MAAs) submitted by Pierre
Fabre and Japan's
Pharmaceuticals and Medical Devices Agency (PMDA) has accepted the
Manufacturing and Marketing Approval (MMA) applications submitted
by Ono Pharmaceutical Co, Ltd.
The regulatory submissions were based on findings from the
pivotal Phase 3 COLUMBUS trial.
COLUMBUS Median Overall Survival Results
Array will
announce additional results from the Phase 3 COLUMBUS trial in an
oral presentation (Abstract #223875) at the American Society of
Clinical Oncology 2018 Annual Meeting on June 4.
Array previously announced that treatment with the combination
of encorafenib 450 mg daily and binimetinib 45 mg twice daily
(COMBO450) reduced the risk of death compared to treatment with
vemurafenib 960 mg daily [hazard ratio (HR) of 0.61, (95% CI 0.47,
0.79, p<0.001)] in patients with BRAF-mutant melanoma in
the Phase 3 COLUMBUS trial.
- The Phase 3 trial showed mOS of 33.6 months for patients
treated with COMBO450, compared to 16.9 months for patients treated
with vemurafenib as a monotherapy.
- As previously reported, the combination of encorafenib and
binimetinib was generally well-tolerated. Grade 3/4 adverse events
(AEs) that occurred in more than 5% of patients receiving the
combination were increased gamma-glutamyltransferase (GGT) (9%),
increased blood creatine phosphokinase (CK) (7%) and hypertension
(6%). The incidence of selected any grade AEs of special interest,
defined based on toxicities commonly associated with commercially
available BRAF+MEK-inhibitor treatments for patients receiving the
combination of encorafenib and binimetinib included: rash (22%),
pyrexia (18%), serous retinopathy including retinal pigment
epithelial detachment (20%) and photosensitivity (5%). Full safety
results of COLUMBUS Part 1 were published in The Lancet
Oncology.
The Lancet Oncology Publication
Detailed results of
the pivotal Phase 3 COLUMBUS trial for the treatment of patients
with BRAF-mutant advanced, unresectable or metastatic
melanoma were published online on March 21,
2018 and in the May 2018 print
edition of The Lancet Oncology.
BEACON CRC PHASE 3 TRIAL
Array will present updated
results from the 30 patient safety lead-in of the Phase 3 BEACON
CRC trial at the ESMO 20th World Congress on
Gastrointestinal Cancer June 20-23,
2018.
Array previously announced updated results from the 30 patient
safety lead-in of the Phase 3 BEACON CRC trial evaluating the
triplet combination of encorafenib, binimetinib and cetuximab, an
EGFR antagonist, in patients with BRAF-mutant CRC whose
disease has progressed after one or two prior regimens at the ASCO
2018 Gastrointestinal Cancers Symposium.
- The estimated mPFS at the time of analysis was 8 months in 29
patients with BRAFV600E-mutant CRC.
- The confirmed overall response rate (ORR) was 48% with 3
complete responses in patients with
BRAFV600E-mutant CRC. Further, the ORR was 62% in
the 16 patients who received only one prior line of therapy.
- These data represent improvements compared to several approved
standard of care benchmarks for this population which range between
4% to 8% ORR and 1.8 and 2.5 months mPFS. [1-4]
- The triplet combination was generally well-tolerated. Two
patients discontinued treatment due to AEs with only one of these
considered related to treatment. The most common grade 3 or 4 AEs
seen in at least 10% of patients were fatigue, urinary tract
infection, increased aspartate aminotransferase (AST) and increased
blood CK.
- Enrollment in the randomized portion of BEACON CRC is ongoing.
BRAF mutations are estimated to occur in 10% to 15% of
patients with CRC and represent a poor prognosis for these
patients.
Encorafenib and binimetinib are investigational medicines and
are not currently approved in any country.
IMMUNO-ONCOLOGY COLLABORATIONS: TRIALS ADVANCING WITH
BRISTOL-MYERS SQUIBB AND MERCK;
TRIAL WITH PFIZER EXPECTED TO START THIRD QUARTER OF 2018
Array is developing binimetinib in combination with PD-1/ PD-L1
checkpoint inhibitors and has announced separate, strategic
collaborations with Bristol-Myers Squibb, Merck and Pfizer, but in
each case, are pursuing a unique trial design to explore different
clinical approaches.
Bristol-Myers Squibb
- The clinical trial continues to advance and is designed to
investigate the safety, tolerability and efficacy of binimetinib in
combination with nivolumab (anti-PD-1 therapy), with and without
ipilimumab (CTLA-4 antibody), in patients with advanced metastatic
microsatellite stable (MSS) CRC and the presence of a RAS
mutation who have received one or two prior regimens.
- The trial is jointly supported by Array and Bristol-Myers
Squibb and sponsored by Array.
Merck
- The clinical trial continues to advance and is designed to
investigate the safety, tolerability and efficacy of binimetinib in
combination with pembrolizumab (anti-PD-1 therapy), with and
without FOLFOX or FOLFIRI (chemotherapy) in patients with CRC whose
tumors are not microsatellite instability-high (MSI-H).
- The trial is sponsored and funded by Merck, with Array
providing binimetinib supply.
Pfizer
- The clinical trial is designed to investigate the safety,
tolerability and efficacy of several novel anti-cancer
combinations, including binimetinib, avelumab (anti-PD-L1 therapy)
and talazoparib (PARP inhibitor) across various tumor types and is
expected to begin during the third quarter of 2018.
- Initially, the focus will be in non-small cell lung cancer
(NSCLC) and pancreatic cancer, with additional indications being
explored at a later stage.
- The trial will be sponsored and funded by Pfizer, with Array
providing binimetinib supply.
FINANCIAL HIGHLIGHTS
Novartis Financial
Commitment
Novartis continues to substantially fund all
ongoing trials with encorafenib and binimetinib that were active or
planned as of the close of the Novartis Agreements in 2015,
including the COLUMBUS Phase 3 trial. Reimbursement revenue from
Novartis was approximately $87
million for the 12 months ended March
31, 2018, of which $24.8
million was recorded in the quarter ended March 31, 2018. Total revenue and upfront payment
collected from Novartis since the start of the 2015 agreement is
$373.5 million.
Third Quarter of Fiscal 2018 Compared to Second Quarter of
Fiscal 2018 (Sequential Quarters Comparison)
- Revenue for the third quarter of fiscal 2018 was
$66.4 million, compared to
$42.2 million for the prior quarter.
The increase was primarily due to an upfront license fee from ASLAN
Pharmaceuticals as well as higher Novartis reimbursement
revenue.
- Cost of partnered programs for the third quarter of
fiscal 2018 was $17.7 million,
compared to $13.7 million for the
prior quarter. The increase was primarily due to higher costs
incurred for the BEACON CRC trial as it continues to advance, as
well as additional resources engaged on collaborations.
- Research and development expense for proprietary
programs was $53.6 million,
compared to $42.6 million in the
prior quarter. The increase was driven by higher activity on the
Novartis transitioned studies and pre-commercial manufacturing
costs for encorafenib and binimetinib.
- Loss from Operations for the quarter was $21.8 million, compared to a loss from operations
of $25.7 million in the previous
quarter. The decrease in net loss was primarily due to increased
revenue, which was partially offset by increased research and
development expense.
- Net loss for the second quarter was $22.9 million, or ($0.11) per share, compared to $34.1 million, or ($0.17) per share, in the prior quarter.
- Cash, Cash Equivalents and Marketable Securities as of
March 31, 2018 were $440 million.
Third Quarter of Fiscal 2018 Compared to Third Quarter of
Fiscal 2017 (Prior Year Comparison)
- Revenue for the third quarter of fiscal 2018 increased
by $33.1 million compared to the same
quarter of fiscal 2017. The increase was primarily due to the ASLAN
Pharmaceuticals upfront license fee.
- Cost of partnered programs increased $10.3 million compared to the third quarter of
fiscal 2017. The increase was primarily due to higher costs
incurred for the BEACON CRC trial, as well as more resources
engaged on collaborations.
- Research and development expense for proprietary
programs increased $7.6 million,
compared to the third quarter of fiscal 2017. The increase was
driven by higher activity on the Novartis transitioned studies and
pre-commercial manufacturing costs for encorafenib and
binimetinib.
- Net loss for the third quarter of fiscal 2018 was
$22.9 million, or ($0.11) per share, compared to $35.3 million, or ($0.21) per share, for the same quarter in fiscal
2017. The decrease in net loss was primarily due to increased
revenue, which was partially offset by increased research and
development expense.
CONFERENCE CALL INFORMATION
Array will hold a
conference call on Wednesday, May 9,
2018 at 9:00 a.m. Eastern Time
to discuss these results and provide an update on the progress of
its key clinical development programs. Ron Squarer, Chief Executive
Officer, will lead the call.
Date:
Wednesday, May 9, 2018
Time:
9:00 a.m. Eastern Time
Toll-Free:
(844) 464-3927
Toll:
(765) 507-2598
Pass Code: 6465079
Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/s5fgkv2a
About COLUMBUS
The COLUMBUS trial, (NCT01909453), is
a two-part, international, randomized, open label Phase 3 trial
evaluating the efficacy and safety of the combination of
encorafenib and binimetinib compared to vemurafenib and encorafenib
monotherapy in 921 patients with locally advanced, unresectable or
metastatic melanoma with BRAFV600 mutation. Prior
immunotherapy treatment was allowed. Over 200 sites across
North America, Europe, South
America, Africa,
Asia and Australia participated in the trial. Patients
were randomized into two parts:
- In Part 1, 577 patients were randomized 1:1:1 to receive
COMBO450, encorafenib, 300 mg daily (ENCO 300), or vemurafenib, 960
mg twice daily alone. The dose of encorafenib in the combination
arm is 50% higher than the single agent maximum tolerated dose of
300 mg. A higher dose of encorafenib was possible due to improved
tolerability when combined with binimetinib. The primary endpoint
for the COLUMBUS trial was an mPFS comparison of the COMBO450 arm
versus vemurafenib. mPFS is determined based on tumor assessment
(RECIST version 1.1 criteria) by a Blinded Independent Central
Review (BICR). Secondary endpoints include a comparison of the mPFS
of COMBO450 arm to that of ENCO300 and a comparison of overall
survival (OS) in patients treated in the COMBO450 arm to that of
vemurafenib alone. Results from Part 1 of the COLUMBUS trial
previously presented at the 2016 Society for Melanoma Research
Annual Congress, showed that COMBO450 more than doubled mPFS in
patients with advanced BRAF-mutant melanoma, with a mPFS of
14.9 months compared with 7.3 months observed with vemurafenib [HR
0.54, (95% CI 0.41-0.71, p<0.0001)]. In the secondary mPFS
comparison of COMBO450 to ENCO300, ENCO300 demonstrated a mPFS of
9.6 months [HR 0.75, (95% CI 0.56-1.00, p=0.051)].
- In Part 2, 344 patients were randomized 3:1 to receive
encorafenib 300 mg plus binimetinib 45 mg twice daily (COMBO300) or
ENCO300. Part 2 was designed to provide additional data to help
evaluate the contribution of binimetinib to the combination of
encorafenib and binimetinib.
As the secondary endpoint comparison of mPFS between the
COMBO450 arm and ENCO300 arm in Part 1 did not achieve statistical
significance, the protocol specified analysis of OS is
descriptive.
About Melanoma
Metastatic melanoma is the most
serious and life-threatening type of skin cancer and is associated
with low survival rates. [5, 6] There are about 200,000 new cases
of melanoma diagnosed worldwide each year, approximately half of
which have BRAF mutations, a key target in the treatment of
metastatic melanoma. [5, 7, 8]
About BEACON CRC
BEACON CRC is the first and only
Phase 3 trial designed to test a BRAF/MEK combo targeted therapy in
BRAF-mutant advanced CRC. BEACON CRC is a randomized,
open-label, global trial evaluating the efficacy and safety of
encorafenib, binimetinib and cetuximab in patients with
BRAF-mutant metastatic CRC whose disease has progressed
after one or two prior regimens. Thirty patients were treated in
the safety lead-in and received the triplet combination of
encorafenib 300 mg daily, binimetinib 45 mg twice daily and
cetuximab per label. Of the 30 patients, 29 had a
BRAFV600E mutation. Microsatellite
instability-high (MSI-H), resulting from defective DNA mismatch
repair, was detected in only 1 patient. As previously announced,
the triplet combination demonstrated good tolerability, supporting
initiation of the randomized portion of the trial.
The randomized portion of the BEACON CRC trial is designed to
assess the efficacy of encorafenib in combination with cetuximab
with or without binimetinib compared to cetuximab and
irinotecan-based therapy. Approximately 615 patients are expected
to be randomized 1:1:1 to receive triplet combination, doublet
combination (encorafenib and cetuximab) or the control arm
(irinotecan-based therapy and cetuximab). The primary endpoint
of the trial is mOS of the triplet combination compared to the
control arm. Secondary endpoints address efficacy of the doublet
combination compared to the control arm, and the triplet
combination compared to the doublet therapy. Other secondary
endpoints include PFS, ORR, duration of response, safety and
tolerability. Health related quality of life data will also be
assessed. The trial will be conducted at over 250
investigational sites in North
America, South America,
Europe and the Asia Pacific region. Patient enrollment is
expected to be completed in 2018.
About Colorectal Cancer
Worldwide, CRC is the third
most common type of cancer in men and the second most common in
women, with approximately 1.4 million new diagnoses in 2012. [9] Of
these, nearly 750,000 were diagnosed in men, and 614,000 in women.
[10] Globally in 2012, approximately 694,000 deaths were attributed
to CRC. [9] In the U.S. alone, an estimated 140,250 patients will
be diagnosed with cancer of the colon or rectum in 2018, and
approximately 50,000 are estimated to die of their disease. [11] In
the U.S., BRAF mutations are estimated to occur in 10% to
15% of patients with CRC and represent a poor prognosis for these
patients. [12, 13, 14, 15] Based on recent prospective historical
data, the prevalence of MSI-H in tumors from patients with
metastatic BRAF-mutant CRC ranged from 14% in a recent Phase
1b/2 trial (NCT01719380) (Array, data
on file) to 18% in a recent Southwestern Oncology Group (SWOG)
randomized Phase 2 trial. [3]
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer and other conditions. Ten
registration studies are currently advancing related to eight
Array-owned or partnered drugs: encorafenib (LGX818), binimetinib
(MEK162), ARRY-797, selumetinib (partnered with AstraZeneca),
danoprevir (partnered with Roche), ipatasertib (partnered with
Genentech), larotrectinib (partnered with Loxo Oncology) and
tucatinib (partnered with Seattle Genetics). For more information
on Array, please go to www.arraybiopharma.com.
References
[1] De Roock et al., Lancet Oncol,
2010
[2] Peeters et al., ASCO 2014
[3] Kopetz et al., ASCO 2017
[4] Seymour et al., Lancet Oncol, 2013 (supplementary
appendix)
[5] Melanoma Skin Cancer. American Cancer Society. Available at:
https://www.cancer.org/cancer/melanoma-skin-cancer.html. Accessed
January 2018.
[6] A Snapshot of Melanoma. National Cancer Institute. Available
at: https://seer.cancer.gov/statfacts/html/melan.html. Accessed
January 2018.
[7] Globocan 2012: Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012.
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed
January 2018.
[8] Klein O, et al. Eur J Cancer 2013
[9] Global Cancer Facts & Figures 3rd Edition. American Cancer
Society. Available at:
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf.
Accessed January 2018.
[10] GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012. Available at:
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed
January 2018.
[11] Cancer Facts & Figures 2018. American Cancer
Society. Available at:
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf.
Accessed January 2018.
[12] Sorbye H, et al. PLoS One. 2015
[13] Vecchione, et al. Cell. 2016
[14] Saridaki et al., PLoS One. 2013
[15] Loupakis et
al., Br J Cancer. 2009
Forward-Looking Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about the timing of the announcement of the results of clinical
trials for our proprietary and our partnered programs, the timing
of the completion or initiation of further development of our
wholly-owned and our partnered programs, including the timing of
regulatory filings or approvals, expectations that events will
occur that will result in greater value for Array, the potential
for the results of ongoing preclinical and clinical trials to
support regulatory approval or the marketing success of a drug
candidate, our ability to partner our proprietary drug candidates
for up-front fees, milestone and/or royalty payments, our future
plans to progress and develop our proprietary programs, our future
capital requirements and the plans of our collaborators to progress
and develop programs we have licensed to them, and our plans to
build a commercial-stage biopharmaceutical company. These
statements involve significant risks and uncertainties, including
those discussed in our most recent annual report filed on Form
10-K, in our quarterly reports filed on Form 10-Q, and in other
reports filed by Array with the Securities and Exchange Commission.
Because these statements reflect our current expectations
concerning future events, our actual results could differ
materially from those anticipated in these forward-looking
statements as a result of many factors. These factors include, but
are not limited to, our ability to continue to fund and
successfully progress internal research and development efforts and
to create effective, commercially-viable drugs; risks relating to
the regulatory approval process for our drug candidates, which may
not result in approval for our drug candidates, cause delays in
development or require that we expend more resources to obtain
approval than expected; risks associated with our dependence on our
collaborators for the clinical development and commercialization of
our out-licensed drug candidates; the ability of our collaborators
and of Array to meet objectives tied to milestones and royalties;
our ability to effectively and timely conduct clinical trials in
light of increasing costs and difficulties in locating appropriate
trial sites and in enrolling patients who meet the criteria for
certain clinical trials; risks associated with our dependence on
third-party service providers to successfully conduct clinical
trials within and outside the United
States; our ability to achieve and maintain profitability
and maintain sufficient cash resources; the extent to which the
pharmaceutical and biotechnology industries are willing to
in-license drug candidates for their product pipelines and to
collaborate with and fund third parties on their drug discovery
activities; our ability to out-license our proprietary candidates
on favorable terms; and our ability to attract and retain
experienced scientists and management. We are providing this
information as of May 9, 2018. We
undertake no duty to update any forward-looking statements to
reflect the occurrence of events or circumstances after the date of
such statements or of anticipated or unanticipated events that
alter any assumptions underlying such statements.
Array BioPharma
Inc.
|
Condensed
Statements of Operations
|
(Unaudited)
|
(in thousands,
except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
Nine Months
Ended
|
|
|
|
|
|
|
March
31,
|
|
March
31,
|
|
|
|
|
|
|
2018
|
|
2017
|
|
2018
|
|
2017
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
Reimbursement
revenue
|
|
|
$
24,751
|
|
$
26,085
|
|
$
65,338
|
|
$
85,354
|
|
Collaboration and
other revenue
|
|
|
10,113
|
|
5,530
|
|
26,629
|
|
17,849
|
|
License and milestone
revenue
|
|
|
31,503
|
|
1,665
|
|
46,364
|
|
13,871
|
|
|
Total
revenue
|
|
|
66,367
|
|
33,280
|
|
138,331
|
|
117,074
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
Cost of partnered
programs
|
|
|
17,712
|
|
7,432
|
|
43,187
|
|
25,303
|
|
Research and
development for proprietary programs
|
|
|
53,636
|
|
46,069
|
|
137,694
|
|
139,101
|
|
Selling, general and
administrative
|
|
|
16,773
|
|
11,714
|
|
40,428
|
|
28,410
|
|
|
Total operating
expenses
|
|
|
88,121
|
|
65,215
|
|
221,309
|
|
192,814
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from
operations
|
|
|
(21,754)
|
|
(31,935)
|
|
(82,978)
|
|
(75,740)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
(expense)
|
|
|
|
|
|
|
|
|
|
|
Loss on
extinguishment and conversion of Notes
|
|
|
—
|
|
—
|
|
(6,457)
|
|
—
|
|
Impairment loss
related to cost method investment
|
|
|
—
|
|
—
|
|
—
|
|
(1,500)
|
|
Realized gains on
investments and other
|
|
|
69
|
|
785
|
|
69
|
|
785
|
|
Change in fair value
of notes payable
|
|
|
(100)
|
|
(1,300)
|
|
(200)
|
|
(2,100)
|
|
Interest
income
|
|
|
1,295
|
|
228
|
|
3,075
|
|
510
|
|
Interest
expense
|
|
|
(2,361)
|
|
(3,095)
|
|
(8,407)
|
|
(9,181)
|
|
|
Total other expense,
net
|
|
|
(1,097)
|
|
(3,382)
|
|
(11,920)
|
|
(11,486)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
$
(22,851)
|
|
$
(35,317)
|
|
$
(94,898)
|
|
$
(87,226)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share
– basic
|
|
|
$
(0.11)
|
|
$
(0.21)
|
|
$
(0.49)
|
|
$
(0.54)
|
Net loss per share
– diluted
|
|
|
$
(0.11)
|
|
$
(0.21)
|
|
$
(0.49)
|
|
$
(0.54)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding – basic
|
|
|
208,994
|
|
169,020
|
|
194,434
|
|
160,689
|
Weighted average
shares outstanding – diluted
|
|
|
208,994
|
|
169,020
|
|
194,434
|
|
160,689
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary Balance
Sheet Data
|
|
|
|
|
(Unadudited)
|
|
|
|
|
(in
thousands)
|
|
|
|
|
|
|
|
|
|
|
March 31,
2018
|
|
June 30,
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash
equivalents and marketable securities
|
|
|
$
439,518
|
|
$
235,055
|
|
|
|
|
|
|
|
Working
capital
|
|
|
$
402,701
|
|
$
200,626
|
|
|
|
|
|
|
|
Total
assets
|
|
|
$
497,007
|
|
$
279,145
|
|
|
|
|
|
|
|
Long-term debt,
net
|
|
|
$
94,555
|
|
$
121,305
|
|
|
|
|
|
|
|
Total stockholders'
equity
|
|
|
$
265,150
|
|
$
11,727
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONTACT:
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-reports-financial-results-for-the-third-quarter-of-fiscal-2018-300645173.html
SOURCE Array BioPharma Inc.